122 related articles for article (PubMed ID: 14592647)
1. Immunophenotyping as a guide for targeted therapy.
Sonneveld P; Pieters R
Best Pract Res Clin Haematol; 2003 Dec; 16(4):629-44. PubMed ID: 14592647
[TBL] [Abstract][Full Text] [Related]
2. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases.
Raponi S; De Propris MS; Intoppa S; Milani ML; Vitale A; Elia L; Perbellini O; Pizzolo G; Foá R; Guarini A
Leuk Lymphoma; 2011 Jun; 52(6):1098-107. PubMed ID: 21348573
[TBL] [Abstract][Full Text] [Related]
3. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia.
Cools J; Mentens N; Furet P; Fabbro D; Clark JJ; Griffin JD; Marynen P; Gilliland DG
Cancer Res; 2004 Sep; 64(18):6385-9. PubMed ID: 15374944
[TBL] [Abstract][Full Text] [Related]
4. Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial.
Vitale A; Guarini A; Ariola C; Meloni G; Perbellini O; Pizzuti M; De Gregoris C; Mettivier V; Pastorini A; Pizzolo G; Vignetti M; Mandelli F; Foà R
Haematologica; 2007 Mar; 92(3):342-8. PubMed ID: 17339183
[TBL] [Abstract][Full Text] [Related]
5. Myeloid antigen co-expression in childhood acute lymphoblastic leukaemia: relationship with in vitro drug resistance.
Den Boer ML; Kapaun P; Pieters R; Kazemier KM; Janka-Schaub GE; Veerman AJ
Br J Haematol; 1999 Jun; 105(4):876-82. PubMed ID: 10554796
[TBL] [Abstract][Full Text] [Related]
6. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children.
Xu F; Taki T; Yang HW; Hanada R; Hongo T; Ohnishi H; Kobayashi M; Bessho F; Yanagisawa M; Hayashi Y
Br J Haematol; 1999 Apr; 105(1):155-62. PubMed ID: 10233379
[TBL] [Abstract][Full Text] [Related]
7. Clinical importance of myeloid-antigen expression in acute lymphoblastic leukemia of childhood.
Wiersma SR; Ortega J; Sobel E; Weinberg KI
N Engl J Med; 1991 Mar; 324(12):800-8. PubMed ID: 1997852
[TBL] [Abstract][Full Text] [Related]
8. Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy.
Mejstríková E; Kalina T; Trka J; Starý J; Hrusák O
Leukemia; 2005 Jun; 19(6):1092-4. PubMed ID: 15830012
[No Abstract] [Full Text] [Related]
9. Determination of myeloid antigen expression on childhood acute lymphoblastic leukaemia cells: discrepancies using different monoclonal antibody clones.
Firat H; Favier R; Adam M; Leverger G; Landman-Parker J; Cayre Y; Douay L
Leuk Lymphoma; 2001 Aug; 42(4):675-82. PubMed ID: 11697497
[TBL] [Abstract][Full Text] [Related]
10. Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo.
Golay J; Di Gaetano N; Amico D; Cittera E; Barbui AM; Giavazzi R; Biondi A; Rambaldi A; Introna M
Br J Haematol; 2005 Feb; 128(3):310-7. PubMed ID: 15667532
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of myeloid antigen markers in adult acute lymphoblastic leukaemia patients: diagnostic and prognostic implications.
Lauria F; Raspadori D; Martinelli G; Rondelli D; Ventura MA; Farabegoli P; Tosi P; Testoni N; Visani G; Zaccaria A
Br J Haematol; 1994 Jun; 87(2):286-92. PubMed ID: 7947269
[TBL] [Abstract][Full Text] [Related]
12. [Immunophenotype characteristics and prognosis of acute leukemia patients with cross expressing lymphoid and myeloid lineage associated antigens].
Jiang NG; Chen XM; Zhu HL; Zhong L; Zeng TT; Jia YQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1405-9. PubMed ID: 21176339
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy of acute myeloid leukemia in 2012: towards individualized therapy.
Foran JM
Hematology; 2012 Apr; 17 Suppl 1():S137-40. PubMed ID: 22507802
[TBL] [Abstract][Full Text] [Related]
14. CD33+ B-cell precursor acute lymphoblastic leukemia in children: a distinct subgroup of B-cell precursor acute lymphoblastic leukemia.
Hara J; Hosoi G; Okamura T; Osugi Y; Ishihara S; Yumura-Yagi K; Kawa-Ha K; Tawa A
Int J Hematol; 1995 Feb; 61(2):77-84. PubMed ID: 7734715
[TBL] [Abstract][Full Text] [Related]
15. The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors.
Hunter HM; Pallis M; Seedhouse CH; Grundy M; Gray C; Russell NH
Br J Haematol; 2004 Oct; 127(1):26-33. PubMed ID: 15384974
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibody therapy of leukaemias and lymphomas.
Jacobs SA; Foon KA
Expert Opin Biol Ther; 2005 Sep; 5(9):1225-43. PubMed ID: 16120052
[TBL] [Abstract][Full Text] [Related]
17. Determination of myeloid antigen expression on childhood acute lymphoblastic leukaemia cells: discrepancies using different monoclonal antibody clones.
Firat H; Favier R; Adam M; Leverger G; Landman-Parker J; Cayre Y; Douay L
Leuk Lymphoma; 2001 Jun; 42(1-2):75-82. PubMed ID: 11699224
[TBL] [Abstract][Full Text] [Related]
18. [Immunophenotyping characteristics of adult patients with acute lymphoblastic leukemia in different ages].
Ma J; Liu YF; Chen SM; Zhang QT; Sun L; Liu LX; Wan DM; Chen SQ; Xie XS; Meng XL; Jiang ZX; Cheng YD; Wang F; Sun H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):942-5. PubMed ID: 20723305
[TBL] [Abstract][Full Text] [Related]
19. FLT3 inhibition in acute myeloid leukaemia.
Knapper S
Br J Haematol; 2007 Sep; 138(6):687-99. PubMed ID: 17655729
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification.
Armstrong SA; Kung AL; Mabon ME; Silverman LB; Stam RW; Den Boer ML; Pieters R; Kersey JH; Sallan SE; Fletcher JA; Golub TR; Griffin JD; Korsmeyer SJ
Cancer Cell; 2003 Feb; 3(2):173-83. PubMed ID: 12620411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
